Beijing Sanyouli Heze Biotech

Sanyou Biopharmaceuticals is a leading international biotechnology company specializing in the discovery and development of innovative antibody drugs. Headquartered in Shanghai with key operations in Beijing and Heze, the company provides integrated R&D services and a robust portfolio of proprietary antibody assets. Their core technology is the Sanyou 4.0 platform, which features super-trillion phage display libraries and advanced screening capabilities for monoclonal, bispecific, and multi-specific antibodies. Sanyou operates as a high-end CRO while also advancing an internal pipeline of candidates for oncology, immunology, and infectious diseases. The company has established numerous partnerships with global pharmaceutical firms to accelerate the development of next-generation biologics.